- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc stock price live, this page displays NASDAQ BMRN stock exchange data. View the BMRN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biomarin Pharmaceutical Inc real time stock price chart below.
What Is the Biomarin Pharmaceutical Inc Stock Price Today?
The Biomarin Pharmaceutical Inc stock price today is 59.59.
What Is the Stock Symbol for Biomarin Pharmaceutical Inc?
The stock symbol for Biomarin Pharmaceutical Inc is "BMRN."
What Stock Exchange Does Biomarin Pharmaceutical Inc Trade On?
Biomarin Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Biomarin Pharmaceutical Inc a Good Stock to Buy?
Determining whether Biomarin Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMRN quote. (ISIN: US09061G1013)
What Is the Biomarin Pharmaceutical Inc Stock Price Today?
The Biomarin Pharmaceutical Inc stock price today is 59.59.
What Is the Stock Symbol for Biomarin Pharmaceutical Inc?
The stock symbol for Biomarin Pharmaceutical Inc is "BMRN."
What Stock Exchange Does Biomarin Pharmaceutical Inc Trade On?
Biomarin Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange.
Is Biomarin Pharmaceutical Inc a Good Stock to Buy?
Determining whether Biomarin Pharmaceutical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BMRN quote. (ISIN: US09061G1013)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.40
60.64
52 wk Range
49.26
66.28
BMRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.4060.64
52 wk Range
49.2666.28
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BMRN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
87.96
Upside
+47.61%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
19 Buy
6 Hold
0 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 87.96
(+47.61% Upside)
Biomarin Pharmaceutical Inc SWOT Analysis
Rare Disease Pionee | BioMarin leads in orphan drug market with innovative therapies, boasting an impressive 81.8% gross margin and stable stock performance |
Financial Strength | Explore BioMarin's robust Q1 2025 results, with $734M in product revenues and projected 9-12% YoY growth, underpinned by a perfect Piotroski Score |
Pipeline Potential | Delve into BioMarin's promising pipeline, including BMN333 for achondroplasia and BMN351 for DMD, poised to drive future growth and market expansion |
Market Challenges | Analyst targets range from $70 to $115, reflecting varied views on BioMarin's ability to navigate increasing competition and maintain market dominance |
Biomarin Pharmaceutical Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of $0.76 beat forecast of $0.74; revenue reached $766M vs. expected $755.94M, though stock fell 1.52% after-hours to $53.24.
- Enzyme therapies grew 6% YoY; Voxzogo segment saw 20% increase in treated children, offset by weaker Roctavian and Kuvan performance.
- Amicus acquisition expected to dilute 2026 EPS but become accretive starting 2027, with contributions from Galafold and Pombiliti/Opfolda.
- Full-year 2026 guidance: revenue of $3.825B-$3.925B (~20% growth); non-GAAP EPS projected at $4.85-$5.05 range.
- Key risks include geopolitical uncertainties in Middle East, rising R&D costs, Amicus integration challenges, and potential market saturation.
Last Updated: 2026-05-10, 07:04 a/m
Read Full TranscriptEarnings
Latest Release
May 04, 2026
EPS / Forecast
0.76 / 0.74
Revenue / Forecast
766M / 755.94M
Compare BMRN to Peers and Sector
Metrics to compare | BMRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBMRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 42.9x | 19.5x | −0.4x | |
PEG Ratio | −0.89 | −1.05 | 0.00 | |
Price/Book | 1.9x | 2.2x | 2.6x | |
Price / LTM Sales | 3.6x | 2.4x | 3.0x | |
Upside (Analyst Target) | 44.3% | 23.3% | 50.8% | |
Fair Value Upside | Unlock | 47.0% | 9.4% | Unlock |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Biomarin Pharma (BMRN) Stock Price Today?
The Biomarin Pharma stock price today is 59.59 USD.
What Stock Exchange Does Biomarin Pharma Trade On?
Biomarin Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Biomarin Pharma?
The stock symbol for Biomarin Pharma is "BMRN."
What Is the Biomarin Pharma Market Cap?
As of today, Biomarin Pharma market cap is 11.52B USD.
What Is Biomarin Pharma's Earnings Per Share (TTM)?
The Biomarin Pharma EPS (TTM) is 1.40.
When Is the Next Biomarin Pharma Earnings Date?
Biomarin Pharma will release its next earnings report on Aug 04, 2026.
From a Technical Analysis Perspective, Is BMRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Biomarin Pharma Stock Split?
Biomarin Pharma has split 0 times.
How Many Employees Does Biomarin Pharma Have?
Biomarin Pharma has 3221 employees.
What is the current trading status of Biomarin Pharma (BMRN)?
As of Jul 18, 2026, Biomarin Pharma (BMRN) is trading at a price of 59.59 USD, with a previous close of 60.00 USD. The stock has fluctuated within a day range of 59.40 USD to 60.64 USD, while its 52-week range spans from 49.26 USD to 66.28 USD.
What Is Biomarin Pharma (BMRN) Price Target According to Analysts?
The average 12-month price target for Biomarin Pharma is 87.96 USD, with a high estimate of 120 USD and a low estimate of 50 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +47.61% Upside potential.
What Is the BMRN Premarket Price?
BMRN's last pre-market stock price is 59.52 USD. The pre-market share volume is 350.00, and the stock has decreased by -0.48, or -0.80%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.